slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 20,371-20,400
Pages 885
Rows per page 30
Arc
20,371-20,400 of 26,550
40
The slide compares six different treatment arms across two scales to demonstrate dose-related exposure.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
41
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
42
Clinical trial update slide.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
43
The slide outlines the methodology for a clinical study, including target sample size (120) and duration (12 months).Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
44
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
45
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
46
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
47
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
48
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
03
Comparison of Tmax metrics and safety profiles for single vs repeat dosing.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
06
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
07
Includes box plot showing 10th/90th percentiles and line chart showing concentration over 20 minutes.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
08
Box plot showing baseline adjusted epinephrine Tmax.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
09
Shows rapid onset of therapeutic benefits for AQST-109.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
10
Clinical trial data comparing sublingual/oral film (AQST-109) vs intramuscular injection.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
11
The chart shows box plots for baseline adjusted Epinephrine Cmax, highlighting differences in drug exposure between the two treatment groups.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
12
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
13
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
04
The slide uses academic citations to establish the clinical relevance of the target protein.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
Includes a scientific diagram of the signaling pathway and references to academic literature.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
Includes a bifurcation diagram illustrating the relationship between SNAIL and ZEB mRNA levels in different cell phenotypes.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
07
The slide uses a visual comparison of biological mechanisms to argue for the superiority of the company's 'Decoy AXL Receptor' approach.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
08
The slide uses a two-column layout to contrast the drug's engineering/profile with its biomarker/IP strategy.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
09
The slide uses a standard organizational structure layout with headshots and a logo grid for credibility.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a horizontal bar chart format to represent clinical trial stages for different drug combinations.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
11
The pie chart visualizes the relative size of the patient populations described in the list.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
04
The diagram illustrates a hub-and-spoke model showing systemic interaction of EMMs across various organs.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · Propose Solution1 hit
06
The slide uses a three-column structure to frame the problem: Market State, Biological Complexity, and Clinical Need.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · Problem StatementLoop · Cost Of Inaction1 hit
08
Axcella Health | Results Presentation Deck | 62 slidesAxcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · Key TakeawaysLoop · Cost Of Inaction1 hit
15
The data shows a statistically significant improvement in the high-dose group at Week 24.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Cost Of Inaction1 hit